Psychosis is a common neuropsychiatric symptom of Parkinson’s disease, and can serve as a clinical marker of advanced disease. Our study aimed to investigate the characteristics of psychosis in a longitudinal PD cohort, to verify baseline clinical risk factors for future psychotic symptoms in de novo PD patients, and to evaluate the relationship between baseline gray matter density in the nucleus basalis of Meynert and future psychotic symptoms in PD. We found lower NBM density at baseline to be associated with increased psychotic symptom burden compared to controls, suggesting utility for the NBM as a neuroimaging biomarker for advanced PD.
This abstract and the presentation materials are available to members only; a login is required.